Is cprx a good stock to buy?
Apr 08, 2022 · Catalyst Pharmaceutical (CPRX) is a Top-Ranked Momentum Stock: Should You Buy? Apr. 6, 2022 at 9:50 a.m. ET on Zacks.com 7 Smart Stocks to Buy Now Under $10
What is%cprx?
CPRX has a Quality Grade of B, ranking ahead of 86.8% of graded US stocks. CPRX's asset turnover comes in at 0.656 -- ranking 47th of 682 Pharmaceutical Products stocks. CHRS, XTNT, and BMY are the stocks whose asset turnover ratios are most correlated with CPRX. The table below shows CPRX's key quality metrics over time.
How does cprx's asset turnover rank among pharmaceutical products stocks?
Apr 01, 2022 · Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CPRX stock has increased by 129.3% and is now trading at $8.07. View which stocks have been most impacted by COVID-19.
What is the market cap of cprx?
Is Cprx a good stock to buy?
The financial health and growth prospects of CPRX, demonstrate its potential to outperform the market. It currently has a Growth Score of A. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
What type of stock is Cprx?
Common StockCommon Stock (CPRX)
Will Cprx stock go up?
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) The 5 analysts offering 12-month price forecasts for Catalyst Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 8.75. The median estimate represents a +40.85% increase from the last price of 8.52.
Is Cprx undervalued?
PB vs Industry: CPRX is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (2.1x).
Is Catalyst Pharmaceuticals a buy?
Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
What is pharmaceutical catalyst?
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. The Company operates through the development and commercialization of drug products.
Where can I buy Cprp Crypto?
How to buy Crypto PerxDownload Coinbase Wallet. ... Choose a Coinbase Wallet username. ... Securely store your recovery phrase. ... Understand and plan for Ethereum network fees. ... Buy and transfer ETH to Coinbase Wallet. ... Use your ETH to buy Crypto Perx in the trade tab.
What does Catalyst Pharmaceuticals make?
Catalyst Pharmaceuticals is a biopharmaceutical company based in Coral Gables, Florida....Catalyst Pharmaceuticals.TypePublic companyProductsFirdapse® (amifampridine) Tablets 10 mg (commercialized 2019)Operating incomeUS$ -35 million (2018)Total assetsUS$ 60.5 million (2018)8 more rows
Is Catalyst Pharmaceuticals a buy right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratin...
How has Catalyst Pharmaceuticals' stock been impacted by Coronavirus?
Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Org...
When is Catalyst Pharmaceuticals' next earnings date?
Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 9th 2022. View our earnings forecast for...
How were Catalyst Pharmaceuticals' earnings last quarter?
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its earnings results on Wednesday, March, 16th. The biopharmaceutical company reported $0.09 ea...
What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?
Catalyst Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, March, 16th. The company provided EPS guidance of for the period. The...
What price target have analysts set for CPRX?
4 brokers have issued 12-month price objectives for Catalyst Pharmaceuticals' stock. Their forecasts range from $8.75 to $12.00. On average, they e...
Who are Catalyst Pharmaceuticals' key executives?
Catalyst Pharmaceuticals' management team includes the following people: Patrick J. McEnany , Chairman, President & Chief Executive Officer ( Li...
Who are some of Catalyst Pharmaceuticals' key competitors?
Some companies that are related to Catalyst Pharmaceuticals include Harmony Biosciences (HRMY) , Corcept Therapeutics (CORT) , Prestige Consumer...
What other stocks do shareholders of Catalyst Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NV...
Recently Viewed Tickers
Catalyst Pharmaceuticals Inc
Visit a quote page and your recently viewed tickers will be displayed here.
Component Grades
Catalyst Pharmaceuticals, Inc.
CPRX POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
CPRX Stock Summary
CPRX scores best on the Value dimension, with a Value rank ahead of 92.25% of US stocks.
CPRX Valuation Summary
With a one year PEG ratio of 112.35, Catalyst Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 80.76% of US stocks.
CPRX's Quality Factors
CPRX's EV/EBIT ratio is 9.4; this is 67.92% lower than that of the median Healthcare stock.
Latest CPRX News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Continue Researching CPRX
Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.
3.5 Analyst's Opinion
Want to do more research on Catalyst Pharmaceuticals Inc's stock and its price? Try the links below:
Is Catalyst Pharmaceuticals a buy right now?
Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
How has Catalyst Pharmaceuticals' stock been impacted by Coronavirus?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock.
When is Catalyst Pharmaceuticals' next earnings date?
Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CPRX shares have increased by 111.1% and is now trading at $7.43. View which stocks have been most impacted by COVID-19.
How were Catalyst Pharmaceuticals' earnings last quarter?
Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022. View our earnings forecast for Catalyst Pharmaceuticals.
What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.10.
What price target have analysts set for CPRX?
Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $195 million-$205 million, compared to the consensus revenue estimate of $163.53 million.
